5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.

Simple item page
dc.contributor.authorAphinives, Potchaviten_US
dc.contributor.authorBhudhisawasdi, Vajarabhongsaen_US
dc.contributor.authorSae-seow, Oturen_US
dc.contributor.authorUttaravichien, Thongueben_US
dc.date.accessioned2009-05-27T19:34:22Z
dc.date.available2009-05-27T19:34:22Z
dc.date.issued2006-11-09en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractOBJECTIVE: To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer. MATERIAL AND METHOD: Between January 1993 and December 2000, 121 from 559 patients with advanced colorectal cancer were treated with chemotherapy. Bolus MMC (10 mg/m2) on first day, 5-FU (600 mg/m2/day) was given as a continuous infusion for 5 days, repeated every 4 weeks for 6 cycles. Toxicity and response were analyzed according to WHO criteria, and survival was analyzed according to Kaplan-Meier methodology. RESULTS: In the chemotherapy group (121 patients), 70 were males and 51 were females, the mean age was 52 years. The ratio of colon and rectal cancer was 0.57. Nearly all patients (88.89%) had tumors with moderate differentiation. Forty patients with liver metastasis showed an overall response rate of 45% (95% CI 35.4-54.6) with a CR in 3 (7.5%) and PR in 15 (37.5%). The median survival was 13.1 months. The regimen was well tolerated with 11.64% of patients experiencing WHO grade 3-4 toxicity. CONCLUSION: The present study has indicated a highly active, acceptable toxic, inexpensive regimen of old drugs to be used as an alternative to the more expensive combination including CPT-11 or oxaliplatin.en_US
dc.description.affiliationDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. potchavit@yahoo.comen_US
dc.identifier.citationAphinives P, Bhudhisawasdi V, Sae-seow O, Uttaravichien T. 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. Journal of the Medical Association of Thailand. 2006 Nov; 89(11): 1885-9en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/41383
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols --adverse effectsen_US
dc.subject.meshCamptothecin --analogs & derivativesen_US
dc.subject.meshColorectal Neoplasms --drug therapyen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshDrug Costsen_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracil --administration & dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMitomycin --administration & dosageen_US
dc.subject.meshOrganoplatinum Compounds --economicsen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Rateen_US
dc.title5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand